Compare Abeona Therapeutics Inc (ABEO) vs Amplify Cybersecurity ETF (HACK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Amplify Cybersecurity ETF — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Amplify Cybersecurity ETF trades at $107.5. The key difference: Amplify Cybersecurity ETF is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | HACK | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $110.27 |
52-Week Low | $4.17 | $70.69 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HACK trades at $110.27, up 3.08% with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF benefits from growing sector spending exceeding $300 billion in 2026, with recent partnerships expanding market reach. Technical indicators show strong trend strength while oscillators suggest potential near-term consolidation.
The outlook remains positive given cybersecurity's essential role in AI adoption, though elevated RSI levels indicate near-term overbought conditions. Key risks include sector competition and market volatility, while institutional momentum supports continued growth potential in the expanding cybersecurity market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →
